Monitor for the announcement of a business combination target within the 24-month window. The $25 million forward purchase commitment from Frazier Life Sciences Public Fund provides a floor for deal financing, but the SPAC's success depends on identifying a viable biotech target. The absence of warrants reduces dilutive overhang compared to typical SPACs.
Executive Summary
Frazier Life Sciences Acquisition Corp. II (FLSC) completed its IPO of 7,500,000 Class A ordinary shares at $10.00 per share, raising $75 million in gross proceeds. The SPAC has a 24-month window to find a biotech target and includes a $25 million forward purchase commitment from an affiliate. The sponsor paid a nominal $0.013 per share for founder shares, creating significant dilution for public shareholders.
Key Financial Metrics
Key Facts
- 7,500,000 Class A ordinary shares sold at $10.00 per share, raising $75,000,000 in gross proceeds
- Underwriting discounts and commissions total $4,500,000 ($0.60/share), including $3,000,000 deferred
- Sponsor purchased 300,000 private placement shares at $10.00/share ($3,000,000 total)
- Founder shares (1,875,000 Class B) purchased for $25,000 (~$0.013/share), convertible 1:1 into Class A
- Forward purchase agreement: Frazier Life Sciences Public Fund committed to buy 2,500,000 shares at $10.00/share ($25,000,000) at business combination close
- $75,000,000 deposited in trust account ($10.00 per public share)
- 24-month deadline to complete initial business combination from closing of this offering
- No warrants issued in this offering
- Sole book-running manager: Jefferies
- Expected listing on Nasdaq Capital Market under symbol FLSC
Financial Impact
IPO raised $75,000,000 in gross proceeds; $75,000,000 placed in trust. Sponsor paid $3,025,000 total ($25,000 for founder shares + $3,000,000 for private placement). Public shareholders face immediate dilution: pro forma net tangible book value per share is $7.60 vs. $10.00 offering price (24% dilution) assuming no redemptions.
Risk Factors
- No target identified yet; risk of failing to complete a business combination within 24 months
- Immediate 24% dilution to public shareholders from sponsor's nominal founder share cost
- Forward purchase agreement subject to investment committee approval — not guaranteed
- Potential for significant additional dilution if anti-dilution provisions on founder shares trigger greater-than-1:1 conversion
- Competition from other SPACs for biotech targets
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-421735 |
| Document: 0001193125-26-421735-index-headers.html | 0001193125-26-421735 |
| Document: 0001193125-26-421735-index.html | 0001193125-26-421735 |
| Document: 0001193125-26-421735.txt | 0001193125-26-421735 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $10.27 | awaiting T+5 | — | $10.30 (+0.29%) |
Oct 22, 2026 3d ago | SC 13G | $10.27 | awaiting T+5 | — | $10.30 (+0.29%) |
Oct 21, 2026 4d ago | SC 13D | $10.27 | awaiting T+5 | — | $10.30 (+0.29%) |
Oct 21, 2026 4d ago | SC 13G | $10.27 | awaiting T+5 | — | $10.30 (+0.29%) |
Oct 21, 2026 4d ago | SC 13G | $10.27 | awaiting T+5 | — | $10.30 (+0.29%) |
Oct 16, 2026 9d ago | SC 13G | $10.35 $10.30 | ▼ −0.48% | ▼ −0.05% | $10.30 (−0.48%) |
Oct 15, 2026 10d ago | Insider Buy | $10.35 $10.30 | ▼ −0.48% | ▼ −0.05% | $10.30 (−0.48%) |
Oct 15, 2026 10d ago | 8-K | $10.35 $10.30 | ▼ −0.48% | ▼ −0.05% | $10.30 (−0.48%) |
Oct 14, 2026 11d ago | 424B4 | $10.49 $10.27 | ▼ −2.10% | ▼ −1.08% | $10.30 (−1.81%) |
Oct 14, 2026 12d ago | EFFECT | $10.29 $10.30 | ▲ +0.10% | ▼ −0.36% | $10.30 (+0.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers